ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.

Bianca Weinstock-Guttman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.